Medical Cannabis Laws Had No Effect on Opioid Treatment or Overdose in Chronic Pain Patients

Medical cannabis laws had estimated effects of less than 0.005 percentage points on CUD or OUD treatment, less than 0.009 points on new treatment initiation, and less than 0.0005 points on overdose-related care (all p > 0.05). The findings do not support the hypothesis that medical cannabis laws reduce opioid-related harms among chronic pain patients.

Difference-in-differences and augmented synthetic control analyses comparing Medicare beneficiaries with chronic noncancer pain in 7 states implementing medical cannabis laws versus 17 comparison states without such laws. Examined CUD and OUD treatment and overdose-related healthcare utilization.

Medical cannabis laws are often justified partly by the potential to reduce opioid harms for pain patients. This rigorous analysis finds no evidence of this effect among Medicare beneficiaries, adding to the mixed evidence on cannabis-opioid substitution.

This adds to growing evidence that the population-level effects of medical cannabis laws on opioid outcomes are minimal. While individual patients may benefit from cannabis-opioid substitution, the effect does not appear at a scale detectable in Medicare claims data.

Medicare population tends to be older and may not represent all chronic pain patients. Claims data cannot determine whether patients actually used medical cannabis. State-level policy implementation varies. The study examines treatment-seeking, not opioid use itself.